Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Non Operating Income (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Non Operating Income for 3 consecutive years, with -$2.4 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 786.42% to -$2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2025, down 255.14% year-over-year, with the annual reading at -$2.6 million for FY2025, 255.14% down from the prior year.
  • Non Operating Income hit -$2.4 million in Q4 2025 for Mangoceuticals, down from -$75850.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $13700.0 in Q1 2025 to a low of -$2.4 million in Q4 2025.
  • Historically, Non Operating Income has averaged -$371096.2 across 3 years, with a median of -$147325.0 in 2025.
  • Biggest five-year swings in Non Operating Income: crashed 2804.7% in 2024 and later skyrocketed 68.61% in 2025.
  • Year by year, Non Operating Income stood at $8233.0 in 2023, then plummeted by 3390.84% to -$270935.0 in 2024, then tumbled by 786.42% to -$2.4 million in 2025.
  • Business Quant data shows Non Operating Income for MGRX at -$2.4 million in Q4 2025, -$75850.0 in Q3 2025, and -$147325.0 in Q2 2025.